About US
Contact us
-
Study suggests hydroxychloroquine doesn't prevent COVID-19. But questions remainPresident Donald Trump said in May that he was taking hydroxychloroquine to guard against COVID-19 infection. But does the anti-malaria drugwork as preventive measure for the novel coronavirus? It do2020/6/8
-
Novartis' Cosentyx chases Lilly's just-approved Taltz with long-term data in spondyloarthritisNovartis' Cosentyx lost a race against Eli Lilly's Taltz after the latter scored an FDA approval in spondyloarthritis earlier this week. But Cosentyx, which facesan FDA review in that indication, is2020/6/5
-
FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumabLast week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which w2020/6/4
-
IMCD appoints new Managing Director in ChinaShanghai, China (June 3rd 2020) –IMCD China, partof the IMCD Group, a global leading distributor of speciality chemicals andfood ingredients, has appointed Andreas Igerl, as Managing Director,effecti2020/6/3
-
Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?AstraZeneca’s CTLA4 candidate tremelimumab has suffered a host of clinical failures that have so far kept it off the market. But new phase 2 results show the company might just be able to use the dru2020/6/2
-
Trump trade adviser, citing 'broken system,' calls for more drug manufacturing in Puerto RicoWelcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. The COVID-12020/6/2
-
AbbVie scores 'game-changer' nod for Oriahnn in uterine fibroidsMost of the recent enthusiasm around AbbVie’s new drugs has centered on immunology meds Skyrizi and Rinvoq, but women’s health med elagolix—known commercially asOrilissain endometriosis—wants a piece2020/6/1
-
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 projectSanofi’s new CEO Paul Hudson has beenmaking his mark in the company’s C-suite, and his latest round of executive shuffling will impact the company's top vaccines job—even as it’s preparing prepping i2020/6/1
-
In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn'tDaiichi Sankyo and partner AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer, leading to a speedyFDA nodat the end of 2019. Now,2020/5/29
-
Gilead CAR-T med Yescarta delivers 93% response rate in slow-growing lymphomaGilead Sciences is working to move CAR-T therapy Yescarta into other types of non-Hodgkin lymphoma (NHL), and if data from an interim trial look-in are any indication, it’s well on its way. In a phas2020/5/29